Targeted radiotherapy with radiolabeled somatostatin analogs.

Nicolas G; Giovacchini G; Muller Brand J; Forrer F

首页> 外文期刊>Endocrinology and Metabolism Clinics of North America >Targeted radiotherapy with radiolabeled somatostatin analogs.

【24h】

Targeted radiotherapy with radiolabeled somatostatin analogs.

机译：使用放射标记的生长抑素类似物进行靶向放疗。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Targeted radiopeptide therapy with (90)Yttrium- or (177)Lutetium-labeled somatostatin analogs has been proven to improve significantly quality of life and survival in patients suffering from metastatic or unresectable neuroendocrine tumors (NETs). Roughly 25% of patients achieve partial remission; progression-free survival is estimated to be 30 to 40 months. A wide range of protocols using different somatostatin analogs, isotopes, injected activity per cycle of administration, and number of cycles are reported. More patient-based therapy protocols are under development, taking into consideration the complexity of NET cell biology, dosimetric issues, and the availability of different radiolabeled analogs. This article reviews the effectiveness and safety of the different protocols and discusses several clinical algorithms used in an attempt to optimize targeted radiopeptide therapy.

机译：事实证明，使用（90）钇或（177）so标记的生长抑素类似物进行靶向放射肽疗法可显着改善患有转移性或不可切除的神经内分泌肿瘤（NETs）的患者的生活质量和生存率。大约25％的患者达到部分缓解;无进展生存期估计为30到40个月。据报道，使用不同的生长抑素类似物，同位素，每个给药周期的注射活性和周期数的方案广泛。考虑到NET细胞生物学的复杂性，剂量学问题以及不同放射性标记类似物的可用性，正在开发更多基于患者的治疗方案。本文回顾了不同方案的有效性和安全性，并讨论了用于优化靶向放射性肽治疗的几种临床算法。

著录项

来源
《Endocrinology and Metabolism Clinics of North America》 |2011年第1期|共20页
作者
Nicolas G; Giovacchini G; Muller Brand J; Forrer F;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Targeted radiotherapy with radiolabeled somatostatin analogs. [J] . Nicolas G, Giovacchini G, Muller Brand J, Endocrinology and Metabolism Clinics of North America . 2011,第1期

机译：使用放射标记的生长抑素类似物进行靶向放疗。
2. 'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs. [J] . Basu S, Abhyankar A, Kand P, Nuclear Medicine Communications . 2011,第7期

机译：68Ga-DOTA-NOC PET / CT和177Lu-DOTA-TATE治疗后扫描之间的“逆向不一致”：合理的解释及其对放射性标记的生长抑素受体类似物的大剂量治疗的意义。
3. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. [J] . Kwekkeboom DJ, Krenning EP, Lebtahi R Neuroendocrinology: International Journal for Basic and Clinical Studies on Neuroendocrine Relationships . 2009,第2期

机译：《 ENETS神经内分泌肿瘤治疗标准共识指南》：采用放射性标记的生长抑素类似物的肽受体放射性核素治疗。
4. Synthesis and radiolabeling of a somatostatin analog for multimodal imaging [C] . W. Barry Edwards, Kexian Liang, Baogang Xu, Optical Molecular Probes for Biomedical Applications; Progress in Biomedical Optics and Imaging; vol.7 no.20 . 2006

机译：生长抑素类似物的合成和放射性标记用于多峰成像
5. Targeted cancer diagnosis with radiolabeled endostatin. [D] . Azhdarinia, Ali. 2005

机译：用放射性标记的内皮抑素进行靶向癌症诊断。
6. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors [O] . Mihaela Ginj, Hanwen Zhang, Beatrice Waser, 2006

机译：对于肿瘤体内肽受体靶向放射性标记的生长抑素受体拮抗剂优于激动剂
7. Induction of the somatostatin receptor on colon carcinoma cells as a target for radiolabeled or cytotoxic somatostatin analogs [O] . Mearadji A. (Amir) 2003

机译：在结肠癌细胞上诱导生长抑素受体作为放射性标记或细胞毒性生长抑素类似物的靶标
8. Interim report on intrathoracic radiotherapy of human small-cell lung carcinoma in nude mice with Re-188-RC-160, a radiolabeled somatostatin analogue [R] . Zamora, P. O., Bender, H., Biersack, H. J., 1995

机译：Re-188-RC-160（一种放射性标记的生长抑素类似物）对裸鼠人小细胞肺癌进行胸内放疗的中期报告

Targeted radiotherapy with radiolabeled somatostatin analogs.

摘要

著录项

相似文献

相关主题

期刊订阅